Baker McKenzie has advised an investment fund managed by Highbridge Capital Management on a financing transaction for Invacare Corporation. Highbridge as lender and Invacare as borrower entered into an USD 104.5 million senior secured credit agreement
Tags :Matthias Courvoisier
Baker McKenzie has advised Cicor on the exercise of its option to reopen its issuance of mandatory convertible bonds due 2027 in an amount corresponding to CHF 40,188,000 and to sell those bonds to One Equity Partners.
Baker McKenzie has acted for CLSA and other underwriters in connection with Joincare Pharmaceutical Group Industry, on global depositary receipts listing on the SIX Swiss Exchange. This transactions proves that the China-Switzerland Stock Connect has
Baker McKenzie Switzerland, along with lawyers from the London and Amsterdam office, has advised Zur Rose Group on the placement of convertible bonds due 2026 and a capital increase through an accelerated bookbuilding (“ABB“) process. Zur
Baker McKenzie Switzerland, along with other Baker McKenzie offices, advised Feintool International Holding (“Feintool”) on its capital increase by approximately CHF 202 million via a rights offering. UBS acted as sole global coordinator and bookrunner while
KSA Group has taken another important step on the way to the new green building “Dreiklang”, KSA’s new ecological construction project. The KSA Group was able to raise CHF 120 million on the capital market
SEBA Bank (“SEBA”) successfully completes its Series C funding round, raising CHF 110 million through the issuance of participation certificates (non-voting shares). The financing round was co-led by a consortium of specialized blockchain and fintech investors,
Occlutech Holding, a specialist provider of minimally invasive structural heart disease devices, addressing congenital heart defects, stroke prevention and heart failure, has successfully completed a private placement of Swedish Depositary Receipts (SDRs) worth SEK 450 million (
The first Swiss SPAC, VT5 Acquisition Company, successfully priced its initial public offering. The listing of the Class A Shares and Redeemable Warrants on
Zur Rose Group, e-commerce pharmacy and medical wholesalers, has concluded its accelerated bookbuilding (ABB) with the issuance of 650’000 new shares at an offer price of CHF 290 and gross proceeds of CHF 188.5 million. The shares were